Bayer plans 3 new drugs, banks on gene and cell therapy allogeneic cancer medicines

German pharma giant Bayer has plans to introduce three news drugs with annual sales potential of $1.22 billion (€1 billion) but these will not offset the fall in revenue the company anticipates from the loss of patents over its two best-sellers.

Stefan Oelrich, the company head, who joined in 2018 from rival Sanofi, acknowledged that the new drugs would not compensate for the effects of the forthcoming patent expiry on both its blood thinner Xarelto and eye medicine Eylea, which will start this year in stages globally. The two drugs generate more than €6bn ($6.2 billion) in annual sales, over a third of Bayer’s pharma revenue. “No company in the world . . . would be able to fill such a gap just at once,” said Oelrich at a media meet on Wednesday.

Bayer Pharma Giant

(Photo: Bayer AG)

Bayer recently announced a partnership with German vaccine maker CureVac to accelerate the development of a Covid-19 vaccine.

Bayer is still struggling from its ill-fated acquisition of Monsanto in 2016 and the slew of lawsuits it inherited for Monsanto’s weed killer Roundup’s carcinogenic effects.

Its share price has dropped by over 50 percent in the last five years. After agrichemicals business pharma is its second-largest revenue puller with annual sales of over €18 billion. “The pipeline is light, especially in oncology, but has some more promising products,” said Sebastian Bray, an analyst at Berenberg.

Bayer has turned its focus to cell and gene therapy in the last two years and spent over €5 billion in acquiring companies specializing in the research and development of these sciences.

“We are aiming to launch at least three new clinical substances per year,” Oelrich revealed. The approval processes in these spaces are less tedious and time-consuming and even the R&D cycles are shorter.

But for these investments to pay-off, it will take at least another four to five years. He said the medium-term impact could be larger, with Bayer working on seven promising cell and gene therapy products in clinical development. Bray said Bayer’s move into this new field was right: “Cell and gene therapy are the higher growth markets in pharma,” he said.

Bayer recently invested $105 million in a funding round in closely held Senti Biosciences, a California-based company using synthetic biology to develop off-the-shelf cell therapies for cancer. It is the third cell therapy company to receive investment from Bayer.

“We believe that synthetic biology will become an important pillar in next-generation cell and gene therapy, and that Senti Bio’s leadership in designing and optimizing biological circuits fits precisely with our ambition to prevent and cure cancer and to regenerate lost tissue function,” Juergen Eckhardt, head of Bayer’s venture arm, called Leaps by Bayer, said in a statement.

Bayer also initially took a minority stake in BlueRock Therapeutics before buying out the company in a $1 billion transaction. Leaps by Bayer also took part in a$215 funding round for Century Therapeutics.

The company is also banking on three new drugs with an annual sales potential of over €1bn. The drugs are—a cancer medicine named Nubeqa; a drug called Finerenone to treat diabetic kidney disease; and a drug to treat menopausal symptoms. The cancer drug has already been launched successfully, the kidney disease drug will be launched this year, and the third medicine is in the last stage of clinical trials and will be released in 2024, most likely.

Subscribe to the nation’s fastest-growing business magazine to get the latest business news delivered to your inbox. 

Anna Domanska
Anna Domanska is an Industry Leaders Magazine author possessing wide-range of knowledge for Business News. She is an avid reader and writer of Business and CEO Magazines and a rigorous follower of Business Leaders.

Recent Posts

Moderna vaccine more effective than Pfizer, study says

Moderna vaccine more effective than Pfizer, study says

Moderna’s Covid-19 vaccine does a slightly better job of preventing coronavirus-related hospitalizations and emergency department visits.
2 days ago
iPhone 13 and iPhone 13 Pro: Specifications, Release Date, Features and much more

iPhone 13 and iPhone 13 Pro: Specifications, Release Date, Features and much more

Apple iPhone 13 Pro and iPhone 13 Pro Max can be a hit with its ever new technology A15 Bionic chip and other cool profound features.
3 days ago
Total signs $27 billion energy deal to fund 1-gigawatt solar power plant

Total signs $27 billion energy deal to fund 1-gigawatt solar power plant

The French oil major, Total, has signed a $27 billion deal to fund a 1-gigawatt solar power plant, and boost oil and gas production in the Middle-East region.
3 days ago
PMI seals $1.51 billion takeover of British inhalation specialist Vectura

PMI seals $1.51 billion takeover of British inhalation specialist Vectura

Philip Morris International (PMI) acquires a 22.6% stake in British inhalation specialist Vecutra closing in on the controversial $1.51 billion takeover.
4 days ago
Apple co-founder Steve Wozniak joins the space race

Apple co-founder Steve Wozniak joins the space race

Wozniak, popularly known as “Woz”, is setting up a private space company with Ripcord co-founder Alex Fielding. In a tweet, Wozniak shared a promotional video for the company c
5 days ago
Auto chip shortage affects its production; factory closures rise

Auto chip shortage affects its production; factory closures rise

Automakers like Peugot, Ford, and Toyota are on the run to regain high-margins from the auto chip making since the pandemic and weather disasters have taken over.
5 days ago